Ascorbate as a cofactor for Fe-and 2-oxoglutarate dependent dioxygenases: Physiological activity in tumour growth and progression

Frontiers in Oncology

Volumn 4, Issue NOV, 2014, Pages

  Kuiper, Caroline ^a,b   Vissers, Margreet C M ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

2 oxoglutarate Fe(II) dependent dioxygenase; Ascorbate; Ascorbic acid; Cancer; Hydroxylation; Hypoxia inducible factor 1; TET enzymes; Tumour microenvironment; Vitamin C

Indexed keywords

2 OXOGLUTARIC ACID; ASCORBIC ACID; DIOXYGENASE; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEMCITABINE;

COLORECTAL CANCER; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; EPIGENETICS; GENE EXPRESSION; HUMAN; HYDROXYLATION; NONHUMAN; PANCREAS CANCER; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; UBIQUITINATION;

EID: 84915763059     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00359     Document Type: Review

References (127)

1. Svirbely, J.L. & Szent-Györgyi, A. The chemical nature of vitamin C. Biochem J 27, 279-285 (1933).
2. Myllylä, R., Kuutti-Savolainen, E.-R. & Kivirikko, K.I. The role of ascorbate in the prolyl hydroxylase reaction. Biochem Biophys Res Commun 83, 441-448 (1978).
3. Loenarz, C. & Schofield, C.J. Physiological and biochemical aspects of hydroxylations and demethylations catalyzed by human 2-oxoglutarate oxygenases. Trends Biochem Sci 36, 7-18 (2011).
4. Schofield, C.J. & Ratcliffe, P.J. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5, 343-354 (2004).
5. Ball, G.F.M. Ascorbic acid: physiology. in Encyclopedia of Food Sciences and Nutrition (ed. Caballero, B.) 324-332 (Academic Press, Oxford, 2003).
6. Hulse, J.D., Ellis, S.R. & Henderson, L.M. Carnitine biosynthesis. beta-hydroxylation of trimethyllysine by an alpha-ketoglutarate-dependent mitochondrial dioxygenase. J Biol Chem 253, 1654-1659 (1978).
7. Lindstedt, G. & Lindstedt, S. Cofactor requirements of γ-butyrobetaine hydroxylase from rat liver. J Biol Chem 245, 4178-4186 (1970).
8. Tsukada, Y., et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature 439, 811-816 (2006).
9. Tahiliani, M., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930-935 (2009).
10. Zhao, X., Yang, Y., Sun, B.-F., Zhao, Y.-L. & Yang, Y.-G. FTO and obesity: mechanisms of association. Curr Diab Rep 14, 1-9 (2014).
11. Singleton, R.S., et al. OGFOD1 catalyzes prolyl hydroxylation of RPS23 and is involved in translation control and stress granule formation. Proc Natl Acad Sci USA 111, 4031-4036 (2014).
12. Lando, D., Peet, D.J., Whelan, D.A., Gorman, J.J. & Whitelaw, M.L. Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science 295, 858-861 (2002).
13. Ito, S., et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466, 1129-1133 (2010).
14. Monfort, A. & Wutz, A. Breathing-in epigenetic change with vitamin C. EMBO Rep 14, 337-346 (2013).
15. Webby, C.J., et al. Jmjd6 catalyses lysyl-hydroxylation of U2AF65, a protein associated with RNA splicing. Science 325, 90-93 (2009).
16. Zheng, G., et al. Sprouts of RNA epigenetics: the discovery of mammalian RNA demethylases. RNA Biol 10, 915-918 (2013).
17. Ma, M., Harding, H.P., O'Rahilly, S., Ron, D. & Yeo, G.S. Kinetic analysis of FTO (fat mass and obesity-associated) reveals that it is unlikely to function as a sensor for 2-oxoglutarate. Biochem J 444(2012).
18. Ge, W., et al. Oxygenase-catalyzed ribosome hydroxylation occurs in prokaryotes and humans. Nat Chem Biol 8, 960-962 (2012).
19. Diliberto, E.J.J., Daniels, A.J. & Viveros, O.H. Multicompartmental secretion of ascorbate and its dual role in dopamine beta-hydroxylation. Am J Clin Nutr 54, 1163S-1172S (1991).
20. Ozer, A. & Bruick, R.K. Non-heme dioxygenases: cellular sensors and regulators jelly rolled into one? Nat Chem Biol 3, 144-153 (2007).
21. Mantri, M., Zhang, Z., McDonough, M.A. & Schofield, C.J. Autocatalysed oxidative modifications to 2-oxoglutarate dependent oxygenases. FEBS J 279, 1563-1575 (2012).
22. Hoffart, L.M., Barr, E.W., Guyer, R.B., Bollinger, J.M. & Krebs, C. Direct spectroscopic detection of a C-H-cleaving high-spin Fe(IV) complex in a prolyl-4-hydroxylase. Proc Natl Acad Sci USA 103, 14738-14743 (2006).
23. Schödel, J., et al. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood 117, e207-217 (2011).
24. Berra, E., et al. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steadystate levels of HIF-1α in normoxia. EMBO J 22, 4082-4090 (2003).
25. Bruick, R.K. & McKnight, S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337-1340 (2001).
26. Epstein, A.C.R., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43-54 (2001).
27. Jaakkola, P., et al. Targeting of HIF-1α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468-472 (2001).
28. Yu, F., White, S.B., Zhao, Q. & Lee, F.S. HIF-1α binding to VHL is regulated by stimulus-sensitive prolyl hydroxylation. Proc Natl Acad Sci USA 98, 9630-9635 (2001).
29. Lando, D., et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16, 1466-1471 (2002).
30. Mariani, Christopher J., et al. TET1-mediated hydroxymethylation facilitates hypoxic gene induction in neuroblastoma. Cell Rep 7, 1343-1352 (2014).
31. Salnikow, K., An, W.G., Melillo, G., Blagosklonny, M.V. & Costa, M. Nickelinduced transformation shifts the balance between HIF-1 and p53 transcription factors. Carcinogenesis 20, 1819-1823 (1999).
32. Hirsilä, M., et al. Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway. FASEB J 19, 1308-1310 (2005).
33. Koivunen, P., Hirsilä, M., Günzler, V., Kivirikko, K.I. & Myllyharju, J. Catalytic properties of the asparagine hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem 279, 9899-9904 (2004).
34. Koivunen, P., et al. Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J Biol Chem 282, 4524-4532 (2007).
35. Pan, Y., et al. Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro. Mol Cell Biol 27, 912-925 (2007).
36. Lu, H., et al. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem 280, 41928-41939 (2005).
37. Pollard, P.J., et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14, 2231-2239 (2005).
38. Pollard, P.J. & Ratcliffe, P.J. Puzzling patterns of predisposition. Science 324, 192-194 (2009).
39. Losman, J.-A. & Kaelin, W.G. What a difference a hydroxyl makes: mutant IDH, (R)- 2-hydroxyglutarate, and cancer. Genes Dev 27, 836-852 (2013).
40. Semenza, G.L. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20, 51-56 (2010).
41. Mansfield, K.D., et al. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-a activation. Cell Metab 1, 393-399 (2005).
42. Chandel, N.S., et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1a during hypoxia. J Biol Chem 275, 25130-25138 (2000).
43. Kaelin Jr, W.G. ROS: really involved in oxygen sensing. Cell Metab 1, 357-358 (2005).
44. Qutub, A.A. & Popel, A.S. Reactive oxygen species regulate hypoxia-inducible factor 1a differentially in cancer and ischemia. Mol Cell Biol 28, 5106-5119 (2008).
45. Hoffman, D.L., Salter, J.D. & Brookes, P.S. Response of mitochondrial reactive oxygen species generation to steady-state oxygen tension: implications for hypoxic cell signaling. Am J Physiol Heart Circ Physiol 292, H101-108 (2007).
46. Salnikow, K., Su, W., Blagosklonny, M.V. & Costa, M. Carcinogenic metals induce hypoxia-inducible factor-stimulated transcription by reactive oxygen speciesindependent mechanism. Cancer Res 60, 3375-3378 (2000).
47. Masson, N., et al. The FIH hydroxylase is a cellular peroxide sensor that modulates HIF transcriptional activity. EMBO Rep 13, 251-257 (2012).
48. Hirsilä, M., Koivunen, P., Günzler, V., Kivirikko, K.I. & Myllyharju, J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxiainducible factor. J Biol Chem 278, 30772-30780 (2003).
49. Myllyharju, J. & Kivirikko, K.I. Characterization of the iron- and 2-oxoglutaratebinding sites of human prolyl 4-hydroxylase. EMBO J 16, 1173-1180 (1997).
50. Clifton, I.J., et al. Structural studies on 2-oxoglutarate oxygenases and related doublestranded ß-helix fold proteins. J Inorg Biochem 100, 644-669 (2006).
51. De Jong, L., Albracht, S.P.J. & Kemp, A. Prolyl 4-hydroxylase activity in relation to the oxidation state of enzyme-bound iron: The role of ascorbate in peptidyl proline hydroxylation. Biochim Biophys Acta 704, 326-332 (1982).
52. Majamaa, K., Gunzler, V., Hanauske-Abel, H.M., Myllylä, R. & Kivirikko, K.I. Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase. J Biol Chem 261, 7819-7823 (1986).
53. Myllylä, R., Majamaa, K., Günzler, V., Hanauske-Abel, H.M. & Kivirikko, K.I. Ascorbate is consumed stoichiometrically in the uncoupled reactions catalyzed by prolyl 4-hydroxylase and lysyl hydroxylase. J Biol Chem 259, 5403-5405 (1984).
54. Nietfeld, J.J. & Kemp, A. The function of ascorbate with respect to prolyl 4-hydroxylase activity. Biochim Biophys Acta 657, 159-167 (1981).
55. Tuderman, L., Myllylä, R. & Kivirikko, K.I. Mechanism of the prolyl hydroxylase reaction. Eur J Biochem 80, 341-348 (1977).
56. Dao, J.H., et al. Kinetic characterization and identification of a novel inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 using a time-resolved fluorescence resonance energy transfer-based assay technology. Anal Biochem 384, 213-223 (2009).
57. Blaschke, K., et al. Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature 500, 222-226 (2013).
58. Chen, J., et al. Vitamin C modulates TET1 function during somatic cell reprogramming. Nat Genet (2013).
59. Minor, E.A., Court, B.L., Young, J.I. & Wang, G. Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine. J Biol Chem 288, 13669-13674 (2013).
60. Yin, R., et al. Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals. J Am Chem Soc 135, 10396-10403 (2013).
61. McNeill, L.A., et al. Hypoxia-inducible factor prolyl hydroxylase 2 has a high affinity for ferrous iron and 2-oxoglutarate. Mol Biosyst 1, 321-324 (2005).
62. Kuiper, C., Dachs, G.U., Currie, M.J. & Vissers, M.C.M. Intracellular ascorbate enhances hypoxia-inducible factor (HIF)-hydroxylase activity and preferentially suppresses the HIF-1 transcriptional response. Free Rad Biol Med 69, 308-317 (2014).
63. Goodwin, J.F. & Whitten, C.F. Chelation of ferrous sulphate solutions by desferrioxamine B. Nature 205, 281-283 (1965).
64. Kaczmarek, M., et al. Metal ions-stimulated iron oxidation in hydroxylases facilitates stabilization of HIF-1αprotein. Toxicol Sci 107, 394-403 (2009).
65. Hallberg, L., Brune, M. & Rossander, L. The role of vitamin C in iron absorption. Int J Vitam Nutr Res Suppl 30, 103-108 (1989).
66. Lynch, S.R. & Cook, J.D. Interaction of vitamin C and iron. Ann NY Acad Sci 355, 32-44 (1980).
67. May, J.M. & Qu, Z.-c. Chelation of intracellular iron enhances endothelial barrier function: a role for vitamin C? Arch Biochem Biophys 500, 162-168 (2010).
68. Flashman, E., Davies, S.L., Yeoh, K.K. & Schofield, C.J. Investigating the dependence of the hypoxia-inducible factor hydroxylases (factor inhibiting HIF and prolyl hydroxylase domain 2) on ascorbate and other reducing agents. Biochem J 427, 135-142 (2010).
69. Nytko, K.J., et al. Vitamin C is dispensable for oxygen sensing in vivo. Blood 117, 5485-5493 (2011).
70. Wilmouth, R.C., et al. Structure and mechanism of anthocyanidin synthase from Arabidopsis thaliana. Structure 10, 93-103 (2002).
71. Bleijlevens, B., et al. Changes in protein dynamics of the DNA repair dioxygenase AlkB upon binding of Fe2+ and 2-oxoglutarate. Biochemistry 51, 3334-3341 (2012).
72. Linster, C.L. & Van Schaftingen, E. Vitamin C: biosynthesis, recycling and degradation in mammals. FEBS J 274, 1-22 (2007).
73. Kall, M.A. Ascorbic acid: properties and determination. in Encyclopedia of Food Sciences and Nutrition (ed. Caballero, B.) 316-324 (Academic Press, Oxford, 2003).
74. Buettner, G.R. & Jurkiewicz, B.A. Catalytic metals, ascorbate and free radicals: combinations to avoid. Radiat Res 145, 532-541 (1996).
75. Hornig, D. Distribution of ascorbic acid, metabolites and analogues in man and animals. Annal NY Acad Sci 258, 103-118 (1975).
76. May, J.M. Vitamin C transport and its role in the central nervous system. in Water Soluble Vitamins, Vol. 56 (ed. Stanger, O.) 85-103 (Springer Netherlands, 2012).
77. Tsukaguchi, H., et al. A family of mammalian Na+-dependent L-ascorbic acid transporters. Nature 399, 70-75 (1999).
78. Corti, A., Casini, A.F. & Pompella, A. Cellular pathways for transport and efflux of ascorbate and dehydroascorbate. Arch Biochem Biophys 500, 107-115 (2010).
79. Du, J., Cullen, J.J. & Buettner, G.R. Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim Biophys Acta 1826, 443-457 (2012).
80. May, J.M. The SLC23 family of ascorbate transporters: ensuring that you get and keep your daily dose of vitamin C. Br J Pharmacol 164, 1793-1801 (2011).
81. Evans, R.M., Currie, L. & Campbell, A. The distribution of ascorbic acid between various cellular components of blood, in normal individuals, and its relation to the plasma concentration. Br J Nutr 47, 473-482 (1982).
82. Savini, I., Rossi, A., Pierro, C., Avigliano, L. & Catani, M.V. SVCT1 and SVCT2: key proteins for vitamin C uptake. Amino Acids 34, 347-355 (2008).
83. Levine, M., et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 93, 3704-3709 (1996).
84. Anthony, H.M. & Schorah, C.J. Severe hypovitaminosis C in lung-cancer patients: the utilization of vitamin C in surgical repair and lymphocyte-related host resistance. Br J Cancer 46, 354-367 (1982).
85. Çaliskan-Can, E., et al. Increased levels of 8-hydroxydeoxyguanosine and its relationship with lipid peroxidation and antioxidant vitamins in lung cancer. Clin Chem Lab Med. 46, 107-112 (2008).
86. Choi, M.-A., Kim, B.-S. & Yu, R. Serum antioxidative vitamin levels and lipid peroxidation in gastric carcinoma patients. Cancer Lett 136, 89-93 (1999).
87. Fiaschi, A.I., Cozzolino, A., Ruggiero, G. & Giorgi, G. Glutathione, ascorbic acid and antioxidant enzymes in the tumour tissue and blood of patients with oral squamous cell carcinoma. Eur Rev Med Pharamcol Sci 9, 361-367 (2005).
88. Lima de Araújo, L., Maciel Barbosa, J., Gomes Ribeiro, A.P., Oliveira dos Santos, A.C. & Pedrosa, F. Nutritional status, dietary intake and serum levels of vitamin C upon diagnosis of cancer in children and adolescents. Nutr Hosp 27, 496-503 (2012).
89. Mayland, C.R., Bennett, M.I. & Allan, K. Vitamin C deficiency in cancer patients. Palliat Med 19, 17-20 (2005).
90. Dudek, H., Farbiszewski, R., Rydzewska, M., Michno, T. & Kozlowksi, A. Evaluation of antioxidant enzymes activity and concentration of non-enzymatic antioxidants in human brain tumours. Wiad Lek 57, 16-19 (2004).
91. Landolt, H., Langemann, H., Probst, A. & Gratzl, O. Levels of water-soluble antioxidants in astrocytoma and in adjacent tumor-free tissue. J Neuro-Oncol 21, 127-133 (1994).
92. Skrzydlewska, E. & Stankiewicz, A. Antioxidant status and lipid peroxidation in colorectal cancer. J Toxicol Env Heal A 64, 213-222 (2001).
93. Langemann, H., Torhorst, J., Kabiersch, A., Krenger, W. & Honegger, C.G. Quantitative determination of water- and lipid-soluble antioxidants in neoplastic and non-neoplastic human breast tissue. Int J Cancer 43, 1169-1173 (1989).
94. Moriarty, M., Mulgrew, S., Malone, J. & O'Connor, M. Results and analysis of tumour levels of ascorbic acid. Irish J Med Sci 146, 74-78 (1977).
95. Kuiper, C., et al. Increased tumour ascorbate is associated with extended disease-free survival and decreased hypoxia-inducible factor-1 activation in human colorectal cancer. Front Oncol 4(2014).
96. Kuiper, C., et al. Low ascorbate levels are associated with increased hypoxiainducible factor-1 activity and an aggressive tumor phenotype in endometrial cancer. Cancer Res 70, 5749-5758 (2010).
97. Hong, S.-W., et al. SVCT-2 in breast cancer acts as an indicator for L-ascorbate treatment. Oncogene (2012).
98. Padayatty, S.J., et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140, 533-537 (2004).
99. Vissers, M.C.M., Gunningham, S.P., Morrison, M.J., Dachs, G.U. & Currie, M.J. Modulation of hypoxia-inducible factor-1 alpha in cultured primary cells by intracellular ascorbate. Free Rad Biol Med 42, 765-772 (2007).
100. Knowles, H.J., Raval, R.R., Harris, A.L. & Ratcliffe, P.J. Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res 63, 1764-1768 (2003).
101. Qiao, H., Li, L., Qu, Z.-c. & May, J.M. Cobalt-induced oxidant stress in cultured endothelial cells: prevention by ascorbate in relation to HIF-1a. Biofactors 35, 306-313 (2009).
102. Gao, P., et al. HIF-dependent antitumorigenic effects of antioxidants in vivo. Cancer Cell 12, 230-238 (2007).
103. Esteban, M.A., et al. Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell 6, 71-79 (2010).
104. Wang, T., et al. The histone demethylases Jhdm1a/1b enhance somatic cell reprogramming in a vitamin-C-dependent manner. Cell Stem Cell 9, 575-587 (2011).
105. Cameron, E. & Pauling, L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 73, 3685-3689 (1976).
106. Cameron, E. & Pauling, L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 75, 4538-4542 (1978).
107. Creagan, E.T., et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. N Engl J Med 301, 687-690 (1979).
108. Moertel, C.G., et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized doubleblind comparison. N Engl J Med 312, 137-141 (1985).
109. Dusing, R.W., et al. Prostate imaging modalities that can be used for complementary and alternative medicine clinical studies. Urol Clin N Am 38, 343-357 (2011).
110. Padayatty, S.J., et al. Intravenously administered vitamin C as cancer therapy: three cases. CMAJ 174, 937-942 (2006).
111. Hoffer, L.J., et al. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 19, 1969-1974 (2008).
112. Riordan, H.D., et al. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J 24, 269-276 (2005).
113. Padayatty, S.J., et al. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. Plos One 5, e11414 (2010).
114. Chen, Q., et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 102, 13604-13609 (2005).
115. Chen, Q., et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA 104, 8749-8754 (2007).
116. Belin, S., et al. Antiproliferative effect of ascorbic acid is associated with the inhibition of genes necessary to cell cycle progression. Plos One 4, e4409 (2009).
117. Cha, J., et al. Ascorbate depletion increases growth and metastasis of melanoma cells in vitamin C deficient mice. Exp Oncol 33, 226-230 (2011).
118. Kasprzak, K.S., et al. Effects of ascorbic acid on carcinogenicity and acute toxicity of nickel subsulfide, and on tumor transplants growth in gulonolactone oxidase knockout mice and wild-type C57BL mice. Toxicol Appl Pharmacol 257, 32-37 (2011).
119. Kim, J., et al. Enhanced antitumor activity of vitamin C via p53 in cancer cells. Free Rad Biol Med 53, 1607-1615 (2012).
120. Verrax, J. & Calderon, P.B. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Rad Biol Med 47, 32-40 (2009).
121. Chen, Q., et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 105, 11105-11109 (2008).
122. Cha, J., et al. Ascorbate supplementation inhibits growth and metastasis of B16FO melanoma and 4T1 breast cancer cells in vitamin C-deficient mice. Int J Oncol 42, 55-64 (2013).
123. Rohwer, N. & Cramer, T. Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Update 14, 191-201 (2011).
124. Wenzel, U., Nickel, A., Kuntz, S. & Daniel, H. Ascorbic acid suppresses druginduced apoptosis in human colon cancer cells by scavenging mitochondrial superoxide anions. Carcinogenesis 25, 703-712 (2004).
125. Espey, M.G., et al. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Rad Biol Med 50, 1610-1619 (2011).
126. Frömberg, A., et al. Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemoth Pharm 67, 1157-1166 (2011).
127. Monti, D.A., et al. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. Plos One 7, e29794 (2012).